GI NURSES CONNECT powered by COR2ED

Useful insights on trial data, safety and real-world considerations for peri-operative immunotherapy in gastric and GEJ cancer. #MedEd

LEVIATHAN data indicate lenvatinib may offer greater second-line efficacy than sorafenib after atezolizumab plus bevacizumab in unresectable HCC, even in patients with primary resistance to immunotherapy.

We are proud to share that more than 50,000 HCPs around the world follow @COR2EDMedEd's programmes to stay up to date with the latest science, and provide their patients with the best possible care 🎉 ~ GI NURSES CONNECT is an initiative of COR2ED ~ 👏 Over 25k HCPs subscribe to the COR2ED YouTube channel to see educational videos as soon as they're released 👏 More than 25k followers stay up to date with #MedEd on the COR2ED social media channels on X, LinkedIn, Instagram, and BlueSky Are you part of our community yet? 🎓 Follow us for engaging videos, podcasts, publications, micro learnings, and more! Our programmes are developed by renowned medical experts and endorsed by Medical Societies & Patient Advocacy Groups ✅ Come and follow us on YouTube! @cor2edtheheartofmedicaledu700" target="_blank" rel="nofollow noopener">youtube.com/@cor2edthehear… #medicaleducation #MedTwitter #OncTwitter #GITwitter

🚨 New on-demand resources! 🚨 Expert insights from the latest gastric and gastroesophageal cancer data from ESMO 2025 📺 Newly-released video & slides from a virtual Experts Knowledge Share Meeting Chair: Dr @LizzySmyth1 (UK) Co-Chairs: Prof. Aziz Zaanan (France) & Prof. Markus Moehler (Germany) The faculty shares insights for clinical practice & discusses data from key clinical trials: ✔️ FORTITUDE-101 ✔️ INTEGRATE IIb ✔️ MATTERHORN ✔️ PHERFLOT ✔️ SKYSCRAPER-07 ✔️ LEAP-014 Get the slides: cor2ed.com/gi-connect/pro… 🤝 This programme is endorsed by @ESDO_tweets, @dice_europe & @WarOnCancer Supported by an Independent Educational Grant from Amgen #MedEd #MedTwitter #ESMO25

‘Peri-operative use of immunotherapy in gastric and GEJ cancer’ A new #MedEd video from Assoc. Prof. Sam Klempner📺 Get expert insights on the current treatment landscape, latest trial data, clinical impact, safety considerations, and more 🤝Endorsed by @WarOnCancer & Esophageal Cancer Action Network 🔗 View the slides: cor2ed.com/gi-connect/pro… Supported by an Independent Educational Grant from AstraZeneca US #RN #OncologyNursing

Gastric/gastroesophageal cancer data from #ESMO 2025: Experts Knowledge Share from @giconnectInfo! 🗓️ 19th November ⏰ 17:00 - 18:15 CET / 11:00 - 12:15 EST 🔗 Register now to secure your place! engage.cor2ed.com/events/esmo-20… Join your peers in a post-ESMO interactive webinar to explore new data and the potential implications for clinical practice The panel will discuss what’s new for - targeted therapy & IO - the peri-operative space - esophageal squamous cell carcinoma (ESCC) 🗣️ PLUS: Q&A between speakers + attendees Don’t miss it! 🤝Endorsed by: @dice_europe This independent programme is supported by an educational grant from Amgen #ESMO25 #MedEd #GIcancer #gastriccancer #ESMO2025 🎬

🎉 @COR2EDMedEd now has over 20,000 YouTube subscribers! 🎉 GI NURSES CONNECT is an initiative of COR2ED - come and find us on YouTube! Join over 20k healthcare professionals who follow us on YouTube to stay up to date with high-quality, engaging medical education programmes from world-renowned experts and in collaboration with Medical Societies and Patient Advocacy groups 🎓 Subscribe ▶️ @cor2edtheheartofmedicaledu700" target="_blank" rel="nofollow noopener">youtube.com/@cor2edthehear… #OncTwitter #MedTwitter #MedEd

📢Just released! Gastric & #gastroesophageal cancer update from #ESMO25! 📺 Dr @LizzySmyth1 shares her #gastric & GE cancer highlights & reviews the latest data from #MATTERHORN trial See more updates from #ESMO ▶️ cor2ed.com/n-connect/prog… This independent programme is supported by COR2ED #MedEd #GastricCancer #GIcancer

📢 Come and visit us in Berlin at #ESMO25! We'll be at Booth 4025 offering FREE profile headshots from our professional photographer, and showcasing our range of high-quality Independent #MedicalEducation programmes across multiple therapy areas. See you there! #IME #MedTwitter #MedEd #OncTwitter #ESMO2025 #ESMO @myESMO

📣 Join the discussion! Experts will review the latest data on gastric & gastroesophageal cancer from #ESMO25 in a virtual Experts Knowledge Share from @giconnectInfo What will new data mean for clinical practice? -> 19th November -> 17:00 -18:15 CET / 11:00 -12:15 EST Register now to save your place: engage.cor2ed.com/events/esmo-20… Topics: -Future of targeted therapy & IO -Peri-operative approaches -Developments in ESCC -Panel discussion/Q&A Meeting Chair: Dr @LizzySmyth1 (UK) Co-Chairs: Prof. Aziz Zaanan (France) & Prof. Markus Moehler (Germany) Endorsed by: @dice_europe This independent programme is supported by an educational grant from Amgen #MedEd #ESMO #ESMO2025 #Gicancer #gastriccancer #Gecancer

mPDAC is notoriously aggressive with a poor prognosis. Most patients are diagnosed at an advanced stage and need chemotherapy as soon as possible. In this podcast, Profs. @DrShubhamPant & @efratdotan discuss how to select and optimise first- and second-line chemotherapeutic options for patients with mPDAC. Watch on YouTube: youtube.com/watch?v=8YxRnj… #GIOnc #MedEd #Oncology #PancreaticCancer This educational programme is supported by an Independent Educational Grant from Ipsen USA

📢 Come and visit us in Berlin at #ESMO25! We'll be at Booth 4025 offering FREE profile headshots from our professional photographer & showcasing our range of high-quality Independent #MedicalEducation programmes across multiple therapy areas. See you there! #IME #MedTwitter #MedEd #OncTwitter #ESMO2025 #ESMO @myESMO

Pancreatic ductal adenocarcinoma (PDAC) is often diagnosed at an advanced, incurable stage and carries a poor prognosis In the second video in this 2-part series, Prof Efrat Dotan explores second-line chemo options and treatment sequencing, with insights from CONKO-003, PANCREOX, and NAPOLI-1 Check out the video on YouTube here: youtube.com/watch?v=DwEUAf… #MedTwitter #Oncology #PDAC #MedEd This educational programme is supported by an Independent Educational Grant from Ipsen USA.

After progression on 1st-line immunotherapy (IO), multiple treatment strategies are available for patients with advanced hepatocellular carcinoma (HCC). Experts Assoc. Prof. Lorenza Rimassa and Dr Amit Singal focus on options for patients who are ineligible for IO or those with progression on IO in Module 4 of this 4-part series; 👉youtube.com/watch?v=r1kZeJ… Also available in the series: Module 1: youtube.com/watch?v=bHF-Td… Module 2: youtube.com/watch?v=9YtE4A… Module 3: youtube.com/watch?v=mNDZu4… #HCC #Immunotherapy #MedEd #MedicalEducation This educational programme is supported by an Independent Educational Grant from Bayer.

Systemic chemo is the standard 1st-line treatment for metastatic PDAC, but targeted therapies and immunotherapies may benefit select patients In video 1 of 2, Prof Eileen O’Reilly reviews key clinical trials including PRODIGE, MPACT, NAPOLI-3, and POLO. Check out the video on YouTube here: youtube.com/watch?v=vIddaa… #MedTwitter #Oncology #PDAC #MedEd This educational programme is supported by an Independent Educational Grant from Ipsen USA.

Discover the expanding role of immunotherapy use in HCC in this 4-part micro e-learning series from @hccconnectinfo #MedEd #HCC #Oncology #GIOncology

Insightful overview from @giconnectInfo with Profs. @EileenMOReilly & @efratdotan on chemotherapy strategies for metastatic pancreatic ductal adenocarcinoma (PDAC) #GIOncology #PDAC #MedEd #OncTwitter #PancreaticOncology